

Attorney Docket No. 49674 CPA (72024)
Serial No. 09/537,858
Filed: March 28, 2000
Amendment and Response to [Non-Final/Final] Office Action dated January 15, 2004
Page 2 of 3

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-23 are cancelled.

- Claim 24. (Previously Added). An isolated amino-terminally truncated RANTES polypeptide comprising residues 2-68 of a RANTES polypeptide according to SEQ ID NO: 2, wherein the truncated RANTES polypeptide lacks NH₂-terminal amino acid residue 1 and has chemokine antagonistic activity.
- Claim 25. (Previously Added) An isolated amino-terminally truncated RANTES polypeptide comprising residues 3-68 of a RANTES polypeptide according to SEQ ID NO: 2, wherein the truncated RANTES polypeptide lacks NH₂-terminal amino acid residues 1-2 and has chemokine antagonistic activity.
- Claim 26. (Previously Added) An isolated amino-terminally truncated RANTES comprising residues 4-68 of a RANTES polypeptide according to RANTES (SEQ ID NO: 2), wherein the truncated RANTES polypeptide lacks NH₂-terminal amino acid residues 1-3 and has chemokine antagonistic activity.
- Claim 27. (Previously Added) An isolated amino-terminally truncated RANTES comprising residues 5-68 of an RANTES polypeptide according to SEQ ID NO: 2, wherein the truncated RANTES polypeptide lacks NH₂-terminal amino acid residues 1-4 and has chemokine antagonistic activity.

Attorney Docket No. 49674 CPA (72024)
Serial No. 09/537,858
Filed: March 28, 2000
Amendment and Response to [Non-Final/Final] Office Action dated January 15, 2004
Page 3 of 3

Claim 28. (Currently Amended) The isolated amino-terminally truncated RANTES of claims 24-27 [26-29], wherein the truncated RANTES polypeptide is in glycosylated form.

Claim 29. (Currently Amended) A pharmaceutical composition comprising an isolated truncated RANTES polypeptide according to any one of claims 24-27 [25-29], wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.


Claim 30. (Currently Amended) The pharmaceutical composition according to claim 29 [31], wherein the isolated truncated RANTES polypeptide is in glycosylated form.

CONCLUSION

Applicants submit that all claims are allowable as written and respectfully request early favorable action by the Examiner. If the Examiner believes that a telephone conversation with Applicants' attorney would expedite prosecution of this application, the Examiner is cordially invited to call the undersigned attorney of record.

Respectfully submitted,

Date: 2/18/2004


Dianne M. Rees, Ph.D.
Reg. No. 45,281
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, MA 02205

Telephone: 617-439-4444
Customer No. 21874

BOS2,434237.1